



## **SMARTDIAGNOS: Sample Concentration Integrated Solid-Phase PCR for Next-Generation of Sepsis Diagnostics**

**Ngo Anh, Tien; Aaydha Chidambara, Vinayaka; Nguyen, Trieu; Golabi, Mohsen; Than Linh, Quyen; Wolff, Anders; Bang, Dang Duong**

*Publication date:*  
2018

*Document Version*  
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

*Citation (APA):*  
Ngo Anh, T., Aaydha Chidambara, V., Nguyen, T., Golabi, M., Than Linh, Q., Wolff, A., & Bang, D. D. (2018). *SMARTDIAGNOS: Sample Concentration Integrated Solid-Phase PCR for Next-Generation of Sepsis Diagnostics*. Abstract from Molecular Diagnostics Europe 2018, Lisboa, Portugal.

---

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

## **SMARTDIAGNOS: Sample Concentration Integrated Solid-Phase PCR for Next-Generation of Sepsis Diagnostics**

Tien Anh Ngo

Vinayaka Aaydha Chidambara; Trieu Nguyen; Mohsen Golabi; Quyen Than Linh[\*]; Anders Wolff[\*]; Bang Duong Dang

Technical University of Denmark, Laboratory of Applied Micro and Nanotechnology, National Food Institute, Lyngby, Denmark

[\*] Technical University of Denmark, Department of Micro and Nanotechnology, BiolabChip Group, Lyngby, Denmark

At the Third International Consensus Definitions in 2016 Sepsis has defined as "life-threatening organ dysfunction caused by a dysregulated host response to infection". Sepsis is one of the ten leading causes of mortality in intensive care units (ICU) worldwide. It is too complicated to determine the exact number of patients suffering sepsis, but numerous studies report that the incidence of sepsis is increasing over time, offsetting declining case-fatality rate. It was estimated that at least 19 million people experience sepsis each year worldwide. In the USA, sepsis causes more than 200 000 deaths each year, and costs exceed \$24 billion per year for the direct health care. In Europe, 27% death was estimated from 35% of patient in ICU suffering sepsis and costs 7-21 billion EUR per year for the health sector. To date, early identification of pathogen causing sepsis is a crucial and unique way to reduce mortality, due to every hour of delay in appropriate antimicrobial therapy increases mortality by 5-10%. Current diagnosis methods for sepsis such as conventional blood culture, MALDI-TOF, Septifast and other nucleic acid-based multiplex amplification techniques are time consume (24- 68 hs) and/or low sensitivity. The H2020 EU funded SMARTDIAGNOS project will generate new diagnostic tools for accurate and earlier pathogen detection and identification. In this study, a number of innovative technologies such as pathogen concentration, direct PCR, solid-phase PCR, supercritical angle fluorescence (SAF) microlens array will be developed and combined into a streamlined point-of-care (POC) and a LAB device to archive ultrasensitive, rapid, and unlimited multiplexing pathogen detection in blood samples. So far, the immune-magnetic beads could efficiently concentrate bacterial pathogen at a low concentration of  $10^1$  to  $10^2$  CFU/mL from the human pathogen spiked blood sample within 40 min. Integration of a direct solid-phase PCR using a Phusion hot start DNA polymerase and optical SAF microlens array in a single polymeric Lab-on-Chip platform allows for highly sensitive and multiplexed pathogen detection and their antimicrobial resistance genes within 3 hours (including sample preparation and target concentration) with a detection limit of 10 CFU/mL of the blood sample. Fast, sensitive, and accurate detection of the pathogen causing sepsis and their AMR genes will improve patient outcome, shorten intensive care stay and thus reduce mortality and health care costs.